Business
Results of mite immunotherapy Acarovac PlusT
Results of mite immunotherapy Acarovac PlusT.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 6156D Allergy Therapeutics PLC 08 July 2016 \n\n \n \n \n \n \n8 July 2016\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \n \nAllergy Therapeutics announces publication of 1-year follow up results of its mite allergoid immunotherapy Acarovac Plus™\n \n~ Significant decreases in symptom scores reported with Acarovac Plus ~\n \n~ Product treatment was proven to be well tolerated and safe ~\n \nAllergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the publication of a 1-year follow-up study of patients using Acarovac Plus™, its unique, microcrystalline tyrosine-adsorbed, house dust mite-allergoid subcutaneous immunotherapy in the peer-review journal Immunotherapy.\n \nA previous study in 2014, led by Dr Albert Roger, Director of the Allergy Unit at Universitari Hospital Trias I Pujol, Badalona, Spain, assessed the tolerability and safety of Acarovac Plus™ in patients with respiratory allergy to Dermatophagoides pteronyssinus under conditions of normal clinical practice. This 1-year follow-up investigation, with the existing patient pool and testing regimen, assessed effectiveness using a nasal provocation test and measurement of immunological markers that are indicative of immunotherapy success.\n \nA statistically significant reduction in symptom scores was observed at both follow-up visits (four weeks and one year), with >50% reduction in symptom scores recorded after one year. Moreover, significant improvements in immunological markers were noted at the follow-up visits. Patients reported statistically significant improvements in satisfaction scores after one year in relation to overall effectiveness and convenience of the treatment.\n \n2016 has seen a significant increase in sales of Acarovac Plus™ to over EUR 1 million in key markets Spain and Portugal, compared to 2015. Sales of house dust mite immunotherapy are expected to increase rapidly over the coming years with over 20% of the population in Europe experiencing an allergic reaction to house dust mites. Therefore, Allergy Therapeutics is continuing to develop Acarovac Quattro™, an ultra-short course therapy utilising the adjuvan...